



INNOVATION FOR GOOD HEALTH

持 續 創 新 樂 享 健 康

上海復星醫

二零二壹年年報

* 僅供識別

V

u
v
w
—
2 ESG^{3~}
u
v
w
ESG
ESG
u
ESG
w

a
a
v
v
2
3
w
w
ESG
—
MSCI ESG
—
w
2021
CSR^{3~} u
w

2021 w

v
w
v
u
v
w
u
2022 3 22
w

u u w v
w w v
w v

{ ir@fosunpharma.com
{ 1289 A

1.

u u u u u u u u

w w w w w w v w

ESG ESG ESG ESG ESG ESG ESG ESG

1.1

1.1.1


a		«V ^a		«		u ^a
«			u	a	—	~
«	u		u	u		u
w		u	v	v		v
u		v	v	u		w
z				u		w
ESG			u		u	ESG
u	ESG		w		u	u
u		u	w		w	u
u		u	v	v	v	u
11	u	4	v	v	w	w
			u			

1.1.2 ESG

ESG		u		w
v	-2	ESG	³ ~u	ESG
u	ESG	w	ESG	ESG
v			«u	v
w	ESG	u	ESG	u

	ESG			u		w		ESG
u		ESG			ESG		wESG	
	ESG	u		ESG		v	v	
	ESG		w					u

u ESG u ESG w 2021 u ESG
w u ESG w




ESG
 $wESG$
 ESG u v ESG u
 ESG w

V


1.2

1.2.1



1.2.2 ESG

ESG
a v
u ESG
w ESG
u u
w ESG
u u
v v
w w
v^a GRI
u
v
w




1.3

u 2 — — 3 (prevention-detection-remediation) u u u u 3

u u u a u «v^a w «v^a — ~ « a u w

«v^a «v^a u u u w

« 8 u u u w



{ u u u u u u u u

u z u u u u z u

u u u u u u u

z u u u u u u



w

w u a w « u w 3

w u u w w u w

u a «v^a v « u v
u v v v w w u w
v v v v w w u w

u u u w
u u w



V

w u u - u 30 u u

2.

2 v v v 3 w u GxP¹ u
u u w
u w

2.1

2.1.1

2 v v 3 u u u u
u u w u u u
u w
2021 u u u 49.75 u 2021
12 31 u v v v 240 w

(SOP)«u u a
—GCP ~u z
w

2 3 w a
«u u w u u u
35 v PCT 26 z 62 w 186 u


¹ GxP ² Good x Practice ³ u

u GMPv GAP w



2.1.2

			u		w		
		2015	a		-	~	«
			®—	~u	v	w	2021 12
			(RA)	u	~v	®—	
31	u		®—	®—	~u	w	
	~v		~	®—	~u	®—	
	u		u	w	2022 2 u	®	10
	u	®	4	HER2	u	u	
	v		w				
2021	6 u			®—			CAR-T
	u	®					(IND)
6		u	8		w	u	
		u	2022 2 u			u	23
		40	u		CAR-T		u
			u		w		
2021	3	u	®—	~		u	CLDT
		w		u		u	
		~					CLDT
		w					
			u				w
			v		u	w	
			v		v	w	u
		Tridem Pharma					
			u				
			2		Artesun®u	w	2021
			w			4,800	

V




2.2





u u GMP2010 u GMP 100%w u Agencyu ~ v WHO ICHQ9— — — — 2010 GMP (Good Manufacturing Practice of Medical Products) 2021 12 31 a 38 v 40 FDAv EMA—European Medicines cGMP

V



2.3

2.3.1



u
2 3 u
w

u u
w

u u
100% w 2021 u
100%

2.4

2.4.1

«V^a
 a
 u
 u
 u
 2021 u
 w

«V^a 2018
 «
 u
 u
 u
 u

«V a
 w
 w
 u
 w

«V a
 v
 w
 w

2.4.2

u
 u
 w
 u
 w
 u
 100%w
 24
 u
 u
 138 u

2.4.3

a
 a
 u
 u
 w
 z
 u
 w

«U
 V
 W
 IT
 u
 w

«V^a
 v
 OA
 u
 u
 w
 u
 z

«
 u
 w
 u

3.

3.1

2021 10 31 u
u u a 2021 { «u (COP26) w
u u a « w u
{² u w u u
u 2030 u 2060 w³ u
v u 2021 u (TCFD)u w
u

3.1.1

v ESG 2021 u w ESG ESG u
v u w u ESG v
ESG u u u ESG
u ESG u
w

3.1.2

ESG 2021 u
w
v u RCP2.6 v u u z RCP8.5 w
w (RCP)2.6 RCP8.5w u w
u u u z RCP8.5 u
w

V



u — — — v
v ~ w u
u u w
u

u 2 3 u w u
u u w
u

u z u u
w

z u
u w

3.1.3


u w
w

w u u v u w u
w u u u w u
w

	u		v		u	
	u		w		w	
w		«u		u		w
2021	12	31	u	5		

3.1.4

v	w	u	v	u	u	u
v	33.9	v	5,546	137.8	u	746.5




u		v		v	
u		u		u	

V


u u u
u v v
u 2021 157.9 w

u u u
u u u
u 2,659 w

u 0.2320212,6530 Td<03CBj/.5%CO 1 Tf0.112 Tc -0.112 Tw 2.047[>]TJ00349>0AE0071



2019	758,143	381,580	376,563	0.35
2020	827,858	225,622	602,236	0.27
2021	900,112	308,755	591,357	0.23



— v ~ u 2020 2021
 u 2019 w v v v v w
 v v w
 v w


3.2

a	«V ^a				«V ^a			
«	u	a	(EHS)		«u	EHS		
w	EHS		EHS	u	v	v	v	
	EHS	w	u	2021	^a	EHS		
			u	EHS		u	EHS	
						u	w	

3.2.1

	v		v		u		EHS
	u		v	v	u	v	
	EHS	w	u		EHS	u	EHS
		w					

ISO14001



EHS

u	v	z	u	u
u	v	11	v	w
u	v	11,943.18	v	3,341.32
w				z


3.2.2

u	v	u	v	u	w
2016	2020	u	EHS	z	u
u			w 2021	u	v
(2021–2025)		EHS	v	u	u
		w	u	EHS	u
		u		w	

2021 2025


•		{ 2025	2020	20%
•		{ 2025	2020	20%
•		{ 2025	2020	20%
•	2025 VOCs	100%		
•		{ 2025	2020	15%
•	(COD)	{ 2025	2020	15%
•		{ 2025	2020	15%
•		{ 2025	2019	10%
•		{ 2025	2020	15%
•		{ 2025	2020	10%
•		{ 2025	2020	15%
•		{	3	


3.2.2

a


	u	z	u	u	v	w	v	w	u
	u	(VOCs)	(NOx)	2021	u	(NOx)	u	(SO ₂)	{
	NOx	SO ₂	NHMC	NO _x	¹⁰	SO ₂			
2019	258	134	36	—	—	—	—	—	—
2020	158	105	37	24.2	—	—	—	—	—
2021	182	101	25	42.9	46.61	25.91	6.45	—	—

2019–2021







u u v u w u 2 v 3
u u 10.6%w
2020

2019	7,091,033	2.48	778	0.27	130	0.046
2020	6,505,479	2.15	655	0.22	88.5	0.03
2021	7,497,581	1.92	704	0.18	146	0.038

2019–2021





V



W 2 V V 3 U V
u 54,173 u 91.5 z w

2019	73,584	25.74	63,629.20	22.26	4,320.80	1.51
2020	49,286	16.26	37,060.20	12.23	5,914.50	1.95
2021	66,328	17.01	60,374.70	15.48	5,953.70	1.53







3.2.3

u	a	«W	u	103.1
303,088	u	V	V	

2.9%u
2020
13%W




v



V


4.



4.1




4.1.1



u
w
u
v
v
v
u
w
w
u
v

v
v
v
w
w
u



u
u
u
w
w
u

V


2021 12 31 u

{

68	563	88	9
50	186	71	3
155	63	14	4
23	16	118	12
13	47	103	9
110	269	2	315
32	47	5	
26	69	2	
335	71	19	

4.1.2

u u w 4
u u w w
—Av By Cy D~u GMP



v v v u v v v
v v w u w w u u
w 2021 u u u
38 w

11

140 670 400 62 75 25 149 137

140 780 578 62 75 25 177 137

100.0% 86.1% 69.2% 100.0% 100.0% 100.0% 84.2% 100.0%


u u u v v v w 2 3
u u u w u u u
u u w

11


u v z w

4.2

4.2.1




4.2.2



V

4.2.3

u u u
2 3 W EHS
u EHS a w
« a u «u 2021 12 31 u 7,193 w w



w u u v 411 w
2021 12 31 u v 411 w

5.

2 3 u w 2
v v v u u
w u u w u
 SHL¹² 2021

5.1

5.1.1




u w u v v v
v u v w u w u u u
w w u u u w a «
u w u u

12 SHL


2021 12 31 u

36,279 u 2020

12.47%W



按僱傭類型劃分員工總數
(人，%)



5.1.2

v	v	u	2	3	w	u
w	a	«	u	u	u	u
	u		w			
{	v	v	v			
{	v	v	v			
{		— {	v	v	v	~
{	v	v	v	v	v	v
—	v	v	u	v	v	v
—	u	w	w	u	u	2
—	u	w		100%	100%	3

5.1.3

u	v	v	v	u	v	w	a	v	«	v	v
v						v		v			

V

u
v OA v u v w
u u u u
u v w u
u u w u
u w w w
u u u v v v
w w w u u w
u

5.2

2 3W u w

5.2.1

u u w
u v u {

YAO	{		u	v	v	v	v	v	v	v
EHS~	u		—	v	v	~u	3			
		u				w				

{		u		u		u		u		u
		u				u				w



Super	{		u		2	YAO	3	u		
		u			w		w			
			w							

{		u		v		v		v		u
		u		u		u		v		
			w					v		

{		v		v		u		u		u
		v		v		u		2		
			w					3u		

5.2.2

2		u		3		u				
		u	2		$^3V^2$		$^3V^2$		3	2
						w		u		



u 2 3 u w
v v w
u u w

總部領導力和職能培訓的平台

設置系統的培養項目，通過MT、基礎、中級、高級領導力的培養，以及各職能條線（投資、財務、EHS）核心崗位人才的培養，建立企業人才梯隊。

附屬公司專業技能培訓基地的平台

員工應知應會的職業技能提升平台；深入挖掘各崗位標準動作、最佳實踐以及困難點，建立各崗位工作技能標準，並加以培訓。

知識和經驗傳承的平台

通過對企業內部案例、內部講師的挖掘與開發、搭建共享平台，將隱性知識顯性化，將個人的知識組織化，並通過培訓和「帶教」進行傳承。

文化理念傳播的平台

傳承和發揚本集團企業文化，在ONE-FOSUN下，使得所有員工學相同、思相近、行相符。

w a — « u pc
w u 500 w
u v w
u w
u

MBA— ~ u v ACCA— ~ w u
u u v u w u
u w
u

V

u {

14

2021

837

19

% 58%

% 53%

% 47%

19

20


% 1.3%

% 98.7%


14

20

5.2.3



按性別劃分員工流失率



5.3

5.3.1

	2	V	V	3	u		u
	v		z		v		u
	u			u		w	u
{		v		u	2021–2025	0.3	u 2025
2020	10%	w		u	SOP	u	u
	u		u		u	w	—
		w 2021	u			282	u
	0.355	u			w		0.17u

5.3.2

			u		u	
		w				v
v		v		u	w	
2	3	u			u	w
		u				

2016–2020		u					
39%	33%	u					
(BBS)	u						
v	v	v	v	v	v	v	w
u							u
u							u
3		u		v	v	u	2
		u		v	v	u	2
						w	3
				264			w



u v u v w v
v v v v u u
u u u w w v


V

6.



u 2 u 3 u 2 u 3
u w u w u u
w u u u

2021 u u 4000 u
4 25 2 3u 2 3 u 2021
3 v u 2 v 3 w





V



2021 10 17 u

u 11 14 24 u

1,308 u 21 w

u

3M N95-9132 ~

4,800 w

u

w

3 w

2021 11 6 u

W

u

W

W

u

u

V

V

3

u

w

u

u

2

³u

2021									
	u	2	3	u					
	v	v	v	v					
	v	v	v	v					
	u	u	w	u	u				
	u	w	w	u	v	v			
150		w							



、药

地址:上海市宜山路1289号

郵編:200233

電話:(86 21) 3398 7000

傳真:(86 21) 3398 7020

網址:www.fosunpharma.com